SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
------------------------
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported) April 8, 2002
------------------------
CELL THERAPEUTICS, INC.
--------------------------------------------------------------------------------
(Exact name of registrant as specified in charter)
Washington 0-28386 91-1533912
--------------------------------------------------------------------------------
(State or other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification No.)
501 Elliott Avenue West, Suite 400, Seattle, WA 98119
--------------------------------------------------------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (206) 282-7100
--------------------------------------------------------------------------------
NOT APPLICABLE
--------------------------------------------------------------------------------
(Former name or former address, if changed since last report.)
Item 5. Other Events
On April 8, 2002, Cell Therapeutics, Inc. entered into a loan agreement, and
related documents, with Dr. James A. Bianco, its President, Chief Executive
Officer, and a member of its board of directors. Pursuant to the loan agreement
and related documents, Cell Therapeutics, Inc. extended a loan of $3.5 million
to Dr. Bianco. The loan is a full-recourse loan and is secured by a mortgage on
certain property owned by Dr. Bianco, as well as 255,381 shares of Cell
Therapeutics, Inc. common stock owned by Dr. Bianco. The loan bears interest at
the six-month LIBOR rate plus 2.25%, adjusted semi-annually (4.55% at April 8,
2002). Interest is due on October 8th and April 8th of each year that the loan
is outstanding and principal is due April 8, 2004.
Item 7. Financial Statements and Exhibits
(c) Exhibits
10.1 Loan Agreement, dated April 8, 2002, by and between Cell
Therapeutics, Inc. and James A. Bianco.
-2-
SIGNATURE
Pursuant to the requirements of the Securities Act of 1934, the Registrant
has duly caused this report to be signed on its behalf by the undersigned
thereunto duly authorized.
CELL THERAPEUTICS, INC.
Date: April 12, 2002 /LOUIS A. BIANCO/
-------------------------------
Name: Louis A. Bianco
Title: Executive Vice President,
Finance and Administration
-3-
EXHIBIT INDEX
Exhibit Description
10.1 Loan Agreement, dated April 8, 2002, by and between Cell Therapeutics,
Inc. and James A. Bianco.
-4-